

ASX Announcement

Melbourne, 18 July 2007

CogState Signs its First Agreement with AstraZeneca

Key points:

- **CogState technology to be used for the first time by AstraZeneca in a clinical trial**
- **AstraZeneca is a global healthcare company**

CogState Ltd (ASX:CGS) announced today that it has signed its first agreement with AstraZeneca for the use of CogState's cognitive testing technology, and associated services.

The agreement with AstraZeneca is consistent with CogState's business strategy to target leading pharmaceutical companies that have substantial central nervous system portfolios of drugs in development, which will require cognitive testing as part of the clinical trial. CogState currently has on-going contracts with companies such as Pfizer, Abbott Laboratories, GlaxoSmithKline, Merck & Co Inc. and Lundbeck A/S.

Mr Brad O'Connor, Chief Executive Officer of CogState, said: "We are working with an increasing number of the leading global pharmaceutical companies that specialise in drug development for central nervous system indications. I am really pleased to see our hard work pay off as we add this new and important customer to our existing base."

About CogState

CogState Ltd (ASX: CGS) specialises in the development and commercialisation of rapid, computerised tests of cognition (brain function). The tests are sold to pharmaceutical, biotechnology, nutraceutical and functional food companies to quantify the effect of drugs or other interventions on human subjects participating in clinical trials.

Since sales into the clinical trials market began in 2004, CogState has secured agreements with organisations including Pfizer, Merck, Centres for Disease Control (USA), ALZA Corporation (a member of the Johnson and Johnson group), Organon USA and GlaxoSmithKline. CogState is currently expanding its existing activities in the US clinical trial markets.

For additional information:

Brad O'Connor
Chief Executive Officer
CogState Ltd.
Ph: 03 9664 1300 or 0411 888 347
boconnor@cogstate.com

Rebecca Piercy
Buchan Consulting
Ph: 02 9237 2800
Mob: 0422 916 422
rpiercy@bcg.com.au